Phase 1 Brain Cancer Trial, Recruiting NCT07141732 Sponsor: Joint Stock Company European Medical Centre Condition: Brain Cancer
Back to Brain Cancer

Phase 1 Brain Cancer Trial, Recruiting

NCT07141732
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You must be between 40 and 75 years old.
  • You must be in reasonably good general health and able to carry out most daily activities (confirm with trial site regarding the specific fitness score used).
  • You must be able to understand and sign a consent form on your own, without help from others.
  • You must have been newly diagnosed with a brain tumor called glioblastoma, identified by brain scans before surgery and confirmed during surgery by examining tumor tissue.
  • Your tumor must be in a location where surgeons can remove all or nearly all of it.
  • The space left after surgery must be large enough to fit a special radiation balloon device used in this trial.
  • If you are a woman who could become pregnant, you must have a negative pregnancy test within 7 days before treatment starts.
  • Your blood test results within 7 days before joining must show your bone marrow is working well enough — including healthy levels of infection-fighting cells, platelets, and red blood cells (confirm with trial site for exact numbers).
  • Your kidney and liver function tests within 7–14 days before joining must show these organs are working within acceptable limits (confirm with trial site for exact numbers).
  • Your urine must show low or no protein levels within 14 days before joining (confirm with trial site for details).
  • If you are taking blood-thinning medications, you must have no active bleeding, and your medication dose must have been stable for at least 14 days before joining.

Who may not be able to join:

  • Your glioblastoma has spread to multiple separate areas of the brain.
  • Your tumor is located in the lower part of the brain (below the main brain) or has spread to the lining of the brain or spinal cord.
  • Your glioblastoma has come back or grown again after previous treatment.
  • You have had radiation treatment to the brain before.
  • Your tumor is located very close to (within about half an inch of) critical brain structures, making it unsafe to deliver the planned radiation.
  • The main tumor area that shows up on contrast scans is larger than 6 cm across (roughly the size of a large plum).
  • You have or have had another cancer, except for certain treated skin cancers or very early-stage cancers that were fully treated.
  • You have or have had any other tumor in the brain.
  • You are pregnant, breastfeeding, or unwilling to use reliable contraception during the trial (applies to women who could become pregnant and sexually active men).
  • You have a condition that makes MRI scans unsafe for you, such as certain metal implants.
  • You have a pacemaker or heart device that cannot be removed and would interfere with the trial.
  • You have a condition that makes it unsafe to have general anaesthesia.
  • You are currently taking part in another clinical trial.
  • You have had serious heart problems (such as a heart attack, chest pain requiring hospital care, or heart failure) within the past 6 months.
  • You have had a stroke or mini-stroke within the past 6 months.
  • You have serious blood vessel disease, active blood clots, or a severe ongoing infection requiring hospital-level antibiotic treatment.
  • You have serious lung, liver, or other major organ problems that could interfere with the trial treatment.
  • You have tested positive for HIV, hepatitis B, hepatitis C, or syphilis.
  • You have had a significant bleeding episode (rated as serious by medical standards) within 30 days before joining.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Aleksey Krivoshapkin, Professor M.D., Joint-Stock Company European Medical Center

Phone: +7 (925) 288 - 59-29

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Joint Stock Company European Medical Centre
Registry
ClinicalTrials.gov
Start date
1 September 2025
Est. completion
1 March 2026

Where this trial is recruiting

🇷🇺 Russia

Primary endpoints

Primary Endpoint - Overall Survival (OS) of patients

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov